In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...

Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 ...

Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered ...

The CANOPY Phase 3 clinical trial randomized 788 adult participants across 18 sites in two cohorts: A) immunocompromised and B) people at risk of contracting SARS-CoV-2 due to regular, unmasked ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

As one of the first FRα ADCs in China entering a pivotal phase 3 clinical trial, BAT8006 has the potential to demonstrate clinically meaningful efficacy across the full spectrum of platinum ...

YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its ...

Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered subcutaneously (SC) in patients with recurrent pericarditis.